HKSE:2315

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-08 13:27 UTC

Last close

n/aHKD

Market data

82.2xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
21.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
12.6%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
20.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
0.27Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

Price is the furthest below its sector's middle: 0.12 against 0.36 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

What it sells, to whom

lens 8 of 9

The filer tagged nothing for this, so there is nothing filed to draw.

Nothing is drawn in its place. The other lenses are unaffected.

This filer tagged no segment and no customer.